AVZO-021 — Investigational Agent
Other · Phase 1 · Avenzo Therapeutics
Mechanism of Action
A selective, orally bioavailable CDK2 inhibitor that blocks cyclin E/CDK2-driven cell-cycle progression, targeting tumors with CCNE1 amplification or resistance to CDK4/6 inhibition.
Investigational Indications
- HR-positive/HER2-negative breast cancer
- CCNE1-amplified ovarian cancer
- Advanced solid tumors